RT Journal Article
SR Electronic
T1 Temporal Trend in Mortality from COVID-19 Associated with Cardiovascular Disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.04.26.23289183
DO 10.1101/2023.04.26.23289183
A1 Sarau, Alexandra
A1 Luo, Shengyuan
A1 Chen, Elaine Yi-Shuan
A1 Gawel, Susan
A1 Desai, Pankaja
A1 Tippireddy, Nagarjuna
A1 Saldanha, Anil J.
A1 Suboc, Tisha
A1 Cloherty, Gavin
A1 Landay, Alan
A1 Volgman, Annabelle Santos
YR 2023
UL http://medrxiv.org/content/early/2023/05/01/2023.04.26.23289183.abstract
AB Background The COVID-19 pandemic has endured for over three years with over twelve variants afflicting humans worldwide. The impact and longevity of the pandemic has driven the medical community and researchers to identify high-risk populations, yet few studies have explored temporal trends during the pandemic. The objective of this study is to investigate trends in all-cause mortality associated with co-morbid cardiovascular disease (CVD) throughout the consecutive waves of the COVID-19 pandemic.Methods A retrospective cohort study was conducted on patients with COVID-19 infection who received care at a tertiary care center in Chicago between March 2020 and September 2022.Multivariable logistic regression was used to investigate associations between co-existing CVD (defined as congestive heart failure, myocardial infarction, cerebrovascular disease, peripheral vascular disease) and mortality, adjusting for age, sex, race, and comorbidities defined in the Charlson comorbidity index.Results The study included 38651 participants (mean age 45 years, 57.6% female, 11.4% with co-existing CVD). All-cause mortality in COVID-19 patients was highest during the Delta wave and remained elevated until the late Omicron wave. Mortality associated with co-existing CVD increased during the early pandemic waves, decreased in the later waves, but remained elevated relative to the overall population. When adjusted for age, sex, and race, all-cause mortality was 2.3-fold higher in patients with co-existing CVD compared to those with non-CVD comorbidities (OR = 2.30, 95% CI 1.95 – 2.62; p < 0.001).Conclusions While overall mortality rates declined toward the later waves of the pandemic, all-cause mortality associated with CVD remained elevated compared to individuals without CVD.What is new?- This study found that individuals with co-existing CVD have 2.3-fold higher risk of all-cause mortality compared to those with non-CVD comorbidities.- Mortality associated with co-existing CVD was highest during the early waves of the pandemic and declined during the later waves, yet remained elevated relative to the overall population.What are the clinical implications?- Increased all-cause mortality in COVID-19 patients with co-morbid CVD may be multifactorial from socioeconomic, psychosocial, behavioral, and biological variables.- Individuals with co-existing CVD who become infected with COVID-19 should be considered an at-risk population for increased mortality.Competing Interest StatementThe authors have declared no competing interest.Funding StatementAbbott Laboratories provided assistance with statistical analysis.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Rush University Institutional Review BoardI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data referred to in the manuscript is included in the tables and figures. Any raw form of the data can be included by request.